Bide Pharmatech Co. Ltd. A (SHG:688073) — Stock Price
Bide Pharmatech Co. Ltd. A (SHG:688073) is currently trading at CN¥73.92 CNY, up 20.00% today. Over the past 52 weeks, shares have ranged between CN¥44.63 and CN¥80.38. This page tracks Bide Pharmatech Co. Ltd. A's live share price on the SHG exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Bide Pharmatech Co. Ltd. A market cap and net worth.
Bide Pharmatech Co. Ltd. A (688073) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Bide Pharmatech Co. Ltd. A's daily closing share price and trading volume on the SHG exchange over the past year, giving a clear view of recent price momentum and liquidity.
Bide Pharmatech Co. Ltd. A Income Statement — Revenue, Profit & Earnings by Year
Bide Pharmatech Co. Ltd. A's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | CN¥1.32 Billion | CN¥1.10 Billion | CN¥1.09 Billion | CN¥833.83 Million | CN¥606.22 Million |
| Cost of Revenue | CN¥734.24 Million | CN¥646.52 Million | CN¥655.12 Million | CN¥463.80 Million | CN¥306.39 Million |
| Gross Profit | CN¥589.57 Million | CN¥455.49 Million | CN¥436.74 Million | CN¥370.03 Million | CN¥299.83 Million |
| Research & Development | CN¥62.72 Million | CN¥59.05 Million | CN¥63.23 Million | CN¥46.07 Million | CN¥34.88 Million |
| SG&A | CN¥120.36 Million | CN¥89.55 Million | CN¥97.18 Million | CN¥59.24 Million | CN¥55.02 Million |
| Total Operating Expenses | CN¥1.08 Billion | CN¥943.38 Million | CN¥963.09 Million | CN¥667.63 Million | CN¥482.16 Million |
| Operating Income | CN¥241.65 Million | CN¥158.63 Million | CN¥128.77 Million | CN¥166.20 Million | CN¥124.06 Million |
| EBITDA | — | — | — | — | — |
| EBIT | — | — | — | — | — |
| Interest Expense | CN¥5.80 Million | CN¥3.32 Million | CN¥2.53 Million | CN¥2.16 Million | CN¥924.13K |
| Income Before Tax | CN¥195.43 Million | CN¥148.02 Million | CN¥126.00 Million | CN¥171.77 Million | CN¥114.56 Million |
| Income Tax Expense | — | — | — | — | — |
| Net Income | CN¥151.74 Million | CN¥117.43 Million | CN¥109.57 Million | CN¥145.97 Million | CN¥97.57 Million |
Bide Pharmatech Co. Ltd. A Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Bide Pharmatech Co. Ltd. A's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | CN¥2.52 Billion | CN¥2.42 Billion | CN¥2.42 Billion | CN¥2.36 Billion | CN¥906.13 Million |
| Total Current Assets | CN¥2.30 Billion | CN¥2.21 Billion | CN¥2.26 Billion | CN¥2.24 Billion | CN¥817.71 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | CN¥100.01 Million | CN¥75.52 Million | CN¥122.54K | CN¥3.97 Million | — |
| Net Receivables | CN¥253.44 Million | CN¥222.95 Million | CN¥235.01 Million | CN¥177.03 Million | CN¥124.68 Million |
| Inventory | CN¥962.01 Million | CN¥760.22 Million | CN¥699.43 Million | CN¥521.86 Million | CN¥476.55 Million |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | CN¥7.56 Million | — | — | — | — |
| Total Liabilities | CN¥471.40 Million | CN¥390.91 Million | CN¥325.49 Million | CN¥283.05 Million | CN¥277.27 Million |
| Total Current Liabilities | CN¥341.82 Million | CN¥345.76 Million | CN¥274.97 Million | CN¥249.07 Million | CN¥249.56 Million |
| Long-term Debt | CN¥83.25 Million | — | — | — | — |
| Net Debt | — | — | — | — | — |
| Total Stockholder Equity | CN¥2.05 Billion | CN¥2.03 Billion | CN¥2.09 Billion | CN¥2.08 Billion | CN¥628.86 Million |
| Retained Earnings | CN¥319.83 Million | CN¥259.92 Million | CN¥224.59 Million | CN¥223.48 Million | CN¥86.89 Million |
Bide Pharmatech Co. Ltd. A Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Bide Pharmatech Co. Ltd. A generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | CN¥28.32 Million | CN¥158.31 Million | CN¥-57.39 Million | CN¥29.87 Million | CN¥-64.88 Million |
| Capital Expenditures | CN¥24.28 Million | CN¥88.35 Million | CN¥61.08 Million | CN¥38.41 Million | CN¥29.20 Million |
| Free Cash Flow | CN¥4.04 Million | CN¥69.97 Million | CN¥-118.47 Million | CN¥-8.54 Million | CN¥-94.09 Million |
| Investing Cash Flow | — | — | — | — | — |
| Financing Cash Flow | — | — | — | — | — |
| Dividends Paid | CN¥79.79 Million | CN¥79.88 Million | CN¥100.03 Million | CN¥83.58K | CN¥188.01K |
| Stock-Based Compensation | — | — | — | — | — |
| Depreciation | CN¥30.37 Million | CN¥28.69 Million | CN¥26.93 Million | CN¥17.84 Million | CN¥10.67 Million |
| Change in Cash | CN¥-193.63 Million | CN¥-168.45 Million | CN¥-230.39 Million | CN¥1.30 Billion | CN¥101.62 Million |
Bide Pharmatech Co. Ltd. A Earnings History — EPS Actual vs. Analyst Estimates
Track Bide Pharmatech Co. Ltd. A's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Apr 19, 2023 | 0.57 | — | — |
| Jan 13, 2023 | 0.74 | — | — |